Opyl Ltd News

Opyl Secures First TrialGen Contract With Brain Vector

Digital health company Opyl (ASX:OPL) secured a contract with mental healthcare firm Brain Vector for the former's AI-driven TrialGen platform, according to a Thursday filing with the Australian Secur

MT NewswiresJun 5 21:42

Opyl Ltd. Advises Investor Caution and Diligence

TipRanksMay 6 23:17

Opyl Ltd Announces Director's Final Interests

TipRanksMay 1 21:17

Opyl Ltd. Advances AI Platform and Streamlines Business

TipRanksApr 30 00:08

Opyl Ltd. Calls for Virtual General Meeting

TipRanksApr 28 22:57

Opyl Expands TrialKey Coverage; Shares Up 38%

Digital health company Opyl (ASX:OPL) expanded its TrialKey.ai platform, increasing its coverage to 350,000 trials from 65,000 and enhancing its ability to predict and optimize clinical research and d

MT NewswiresApr 28 20:40

Opyl to Divest Opin Business

Opyl (ASX:OPL) signed a binding sale and purchase agreement to divest its Opin business, allowing the company to focus on high-growth, artificial intelligence-related ventures, according to a Tuesday

MT NewswiresApr 22 21:36

Opyl Divests Subsidiary Opin to Focus on Development of AI Clinical Trial Platform

Opyl (ASX: OPL) will divest its clinical trial recruitment subsidiary Opin to an entity controlled by global health technology entrepreneur Dr Hugo Stephenson.

Small CapsApr 22 20:51

Opyl Receives Offer for Patient Recruitment Business

Opyl (ASX:OPL) received a non-binding offer to acquire its patient candidate recruitment business, Opin, from Trial Screen for AU$1 and 20% of the equity in Trial Screen. Trial Screen is an entity con

MT NewswiresMar 22 02:29

Opyl Requests Trading Halt After Receiving Offer For Opin Business

Opyl (ASX:OPL) requested a halt in the trading of its securities Wednesday afternoon after receiving a non-binding offer to acquire the company's Opin business, according to a same-day filing with the

MT NewswiresMar 20 03:33

Opyl Chair Stepping Down in End-April

Opyl (ASX:OPL) said Mark Ziirsen will step down as nonexecutive chair, effective April 30. Ziirsen joined the company's board in September 2020 and started serving as chair in August 2022, according t

MT NewswiresMar 15 01:05

Opyl Raises Nearly AU$900,000 From Rights Issue Shortfall Placement

Opyl (ASX:OPL) raised AU$886,200 from the successful placement of a rights issue shortfall. This brought the total funds raised from the rights offer to about AU$1.4 million through the issue of 47,77

MT NewswiresFeb 9 01:14

Opyl Grows Cash Receipts for Fiscal Q2

Opyl (ASX:OPL) reported cash receipts from customers of AU$201,000 for the second quarter ended Dec. 31, 2023. This was higher than the digital health company's cash receipts of AU$50,000 in the prior

MT NewswiresJan 31 02:39

Opyl Receives Commitments for Potential Shortfall

Opyl (ASX:OPL) received commitments for any potential remaining shortfall under the current nonrenounceable rights issue offer to raise up to AU$1.4 million. Including the recent AU$580,000 placement,

MT NewswiresJan 1 23:29

Opyl Appoints Interim CEO

Digital health company Opyl (ASX:OPL) appointed Saurabh Jain as interim chief executive, effective Friday. Jain recently joined the Spacetalk (ASX:SPA) board where he stepped into the role of acting C

MT NewswiresNov 23, 2023 22:50

Opyl Secures R&D Tax Rebate for Fiscal Year 2023

Opyl (ASX:OPL) secured a tax rebate worth AU$530,580 for the fiscal year ended June 30 from the Australian government's research and development tax incentive scheme, the medical technology firm said

MT NewswiresSep 22, 2023 03:48